Related Experiment Video
Updated: Sep 17, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study
Yan Ling1, Xiao-Dong Jiao1, Bao-Dong Qin1
1Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Introduction:
Providing precise oncologic treatment for patients with refractory solid tumors is still an unmet need in clinical practice. This study aimed to assess whether treatments recommended by a molecular tumor board (MTB) can improve clinical outcomes in patients with refractory solid tumors.
Methods:
We screened all patients with refractory solid tumors during the period from 2017 to 2022 at the authors' center. The patients with actionable molecular alterations (mainly including druggable tier 2 genetic variants identified using next-generation sequencing [NGS]) were presented to MTB. We compared the overall survival (OS) and progression-free survival (PFS) between the patients treated with a matched therapy recommended by MTB and those who did not receive the MTB-recommended therapy. Patients with no actionable molecular alterations served as an additional control.
Results:
A total of 338 patients with refractory solid tumors were screened. Among the 305 patients for whom NGS testing was conducted, 217 patients available for survival outcomes were included in the final analysis. A total of 129 patients had at least one actionable molecular alteration and were presented to MTB; 82 received the MTB-recommended therapy, while the remaining 47 did not. Those who received the recommended therapy had significantly longer median OS (17.7 vs. 4.4 months; HR 0.31, 95% CI: 0.14-0.66; P < .001) and median PFS (7.0 vs. 2.3 months, HR 0.32, 95% CI: 0.16-0.65; P < .001).
Conclusions:
MTB improves oncologic prognosis in patients with refractory solid tumors, and matching MTB-recommended therapy is an independent factor for OS and PFS.
Insights
Treatments recommended by a molecular tumor board (MTB) significantly improve overall survival (OS) and progression-free survival (PFS) for patients with refractory solid tumors. Matching MTB-recommended therapy is an independent factor for better oncologic outcomes.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Refractory solid tumors present a significant clinical challenge with limited treatment options.
- Molecular tumor boards (MTBs) aim to personalize cancer treatment based on genetic alterations.
Purpose of the Study:
- To evaluate if treatments recommended by an MTB improve clinical outcomes in patients with refractory solid tumors.
- To assess the impact of MTB-recommended therapy on overall survival (OS) and progression-free survival (PFS).
Main Methods:
- Retrospective analysis of 338 patients with refractory solid tumors from 2017-2022.
- Next-generation sequencing (NGS) identified actionable molecular alterations in 129 patients presented to the MTB.
- Comparison of OS and PFS between patients receiving MTB-recommended therapy and those who did not.
Main Results:
- 217 patients with available survival data were analyzed.
- Patients receiving MTB-recommended therapy showed significantly longer median OS (17.7 vs. 4.4 months) and PFS (7.0 vs. 2.3 months).
- MTB-recommended therapy was associated with a hazard ratio of 0.31 for OS and 0.32 for PFS.
Conclusions:
- Molecular tumor board recommendations improve oncologic prognosis in refractory solid tumors.
- Matching therapy based on MTB recommendations is an independent predictor of improved OS and PFS.
Related Concept Videos
02:56Treatment Resistant Cancers
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...